AUNA SA-CLASS A (NYSE:AUNA) Stock Falls 7% After Q3 2025 Earnings Miss Estimates

Recent Performance AUNA SA-CLASS A (NYSE:AUNA) reported third-quarter 2025 financial results that fell short of analyst expectations, triggering a significant negative market reaction. Following the earnings release, the stock experienced a sharp decline of approximately 7.25% in after-market trading. This immediate sell-off reflects investor disappointment with the company's top and bottom-line performance during the quarter.

Earnings and Revenue Analysis The company's financial results for Q3 2025 missed consensus estimates on key metrics, which appears to be the primary driver behind the negative investor sentiment. The performance highlights a divergence between expectations and the company's actual operational and financial delivery for the period.

• Revenue: Reported consolidated revenue of S/1,117 million (approximately $1.09 billion USD), falling short of the analyst estimate of $1.16 billion USD.
• Earnings Per Share (EPS): Reported Adjusted EPS of S/0.71 (approximately $0.68 USD), below the analyst consensus estimate of $0.84 USD.
• Profitability: Adjusted EBITDA decreased by 5% on a constant currency basis to S/232 million, with the margin contracting by 1.3 percentage points to 20.8%.

The revenue shortfall was primarily driven by a 12% decline in Mexico operations, where the company faced softer demand for medical procedures and operational challenges related to system implementations and physician relationships. This was partially offset by growth in Peru and Colombia, where local currency revenues increased by 9% and 4%, respectively.

Operational Highlights and Regional Performance Auna's third-quarter performance revealed a tale of three distinct markets, with operational resilience in some regions failing to fully offset financial headwinds in others. The company's integrated healthcare platform showed strength in its established markets while continuing to navigate challenges in its expansion territory.

In Peru, the company delivered a robust performance with both the Oncosalud and Healthcare Services segments showing strength. Growth was supported by increased memberships, pricing adjustments, and improved operational efficiency, particularly in oncology where the Medical Loss Ratio improved to 49.3%. Colombia also demonstrated strong results, achieving double-digit growth in Adjusted EBITDA as the company successfully diversified its payor mix and optimized resource utilization. The Mexican operations, however, presented ongoing challenges. Despite a second consecutive quarter of growth in surgeries and oncology services, the segment reported declining revenues and profitability due to sluggish procedure volumes and transitional issues with new hospital information systems.

Capital Structure and Strategic Initiatives Beyond the quarterly earnings, Auna made significant progress in strengthening its financial foundation. The company maintained a stable leverage ratio of 3.6x Net Debt-to-Adjusted EBITDA and completed a substantial $765 million debt refinancing after the quarter ended. This refinancing extends debt maturities and reduces interest costs, supporting the company's medium-term target of reducing leverage below 3x. Management also highlighted strategic partnerships, including the collaboration with Sojitz, as key initiatives to drive future growth while maintaining their deleveraging path.

Looking Ahead The press release did not provide specific quantitative financial guidance for the upcoming quarters or full year that could be directly compared to analyst estimates. For the fourth quarter of 2025, analysts are currently projecting revenue of $1.11 billion and full-year 2025 revenue of $4.54 billion. Investors will likely focus on the company's upcoming earnings call for more clarity on the timeline for resolving operational challenges in Mexico and the expected pace of the company's return to stronger growth metrics.

For a detailed overview of historical earnings, future estimates, and analyst projections, review the earnings and estimates data for AUNA.

Disclaimer: This article presents factual information from recent earnings reports and market data for informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.